You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
BACK TO ALL NEWS/

09-09-2019

2019 First Half Results General Investor Call

Following the release of its 1H 2019 results Kedrion S.p.A. is pleased to arrange a General Investor Call

Date & Time: Wednesday 11 September 2019 @ 09.30 UKT / 10.30 CET

Dial-in:

ITALY: +39 02 805 88 11
UK: +44 121 281 8003
FRANCE: +33 170918703
GERMANY: +49 69255114451
SPAIN: +34 917699497

The Company will be represented by:
Simone Boaglio – Chief of Central Services
Peer Hansen – Chief Financial Officer
Pasquale Fraiese – Head of Finance
 

Registration needed, please make sure to dial-in on time.

Link to Investor Presentation will follow ahead of the call.

DOWNLOAD THE H1 2019 RESULTS PRESENTATION

For further information, please write to investor@kedrion.com.

 

About Kedrion

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.

Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,600 employees and a commercial presence in approximately 100 countries worldwide.

Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.

Additional information about Kedrion can be found at kedrion.com.

For more information please contact: investor@kedrion.com